ClinicalTrials.gg
CompletedNCT01388491Updated Dec 6, 2021Results posted

A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women

A Phase 2 interventional study of desogestrel/ethinyl estradiol and ethinyl estradiol and desogestrel/ethinyl estradiol in Hemostasis and Oral Contraceptive, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 27 sites in 4 countries. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-06.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Thrombosis with a site in Spain — 4 open to participants now, 6 under way, none of them phase 3. Thrombosis · Spain.

Enrollment
16th of 32
293 · median 261
Started
2011
with 1 other
Phase 2
3 of 49
none open now
Registered
14th of 49
by date

Among the 49 studies in Thrombosis with a site in Spain, this one is the 16th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 14th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

4 of the 49 studies in Thrombosis with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Thrombosis with a site in Spain, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the impact of DR-102, a 28-day oral contraceptive compared to a standard 28-day oral contraceptive regimen on hemostatic parameters in healthy women.

03

Conditions studied

  • Hemostasis
  • Oral Contraceptive

Browse trials for

Keywords

  • Contraception
  • Hemostasis
  • Blood Coagulation
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal, non-pregnant, non-lactating women age 18-40 years old
  • (BMI) ≥18 kg/m² and \<30 kg/m²
  • Regular spontaneous menstrual cycle
  • Others as dictated by FDA-approved protocol

Exclusion criteria

Exclusion Criteria:

  • Any condition which contraindicates the use of combination oral
  • Any history of, or active, deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease within one year of screening
  • Thrombophlebitis or thromboembolic disorders; known or suspected clotting disorders; thrombogenetic valvulopathies or rhythm disorders
  • Others as dictated by FDA-approved protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
293 participants (actual)

Study arms

  • Experimental
    Treatment I: (DR-102)

    21 days of combination active pills (containing 150 mcg desogestrel \[DSG\]/20 mcg ethinyl estradiol \[EE\]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles

    Drug: desogestrel/ethinyl estradiol and ethinyl estradiol

  • Active comparator
    Treatment II

    21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles

    Drug: desogestrel/ethinyl estradiol

Interventions

06

What researchers measure

Primary outcomes

  1. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels

    Normal range for this hemostatic parameter was 41 to 372 pmol/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

Secondary outcomes

  1. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer

    Normal range for this hemostatic parameter was 0 to 729 mcg/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  2. Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen

    The normal range for this hemostatic parameter was 50% to 147%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  3. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity

    The normal range for this hemostatic parameter was 70% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  4. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin

    Normal range for this hemostatic parameter was 75% to 130%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  5. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity

    Normal range for this hemostatic parameter was 70% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  6. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII

    Normal range for this hemostatic parameter was 60% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  7. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII

    Normal range for this hemostatic parameter was 50% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  8. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance

    This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 2.00 to 3.36. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  9. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance

    This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 0.32 to 1.79. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  10. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin

    Normal range for this adrenal parameter was 1906.448 to 4520.504 mg/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  11. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol

    Normal range for this adrenal parameter was 85.6 to 618.2 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  12. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)

    Normal range for this parameter was 0.35 to 5.5 mIU/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

  13. Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin

    Normal range for this parameter was 28 to 146 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

    Time frame: Baseline through Month 6

07

Results

Posted Nov 27, 2013

Participant flow

Of the 351 healthy women screened for enrollment, 293 at 26 centers in the European Union (EU) (21 centers) and Israel (5 centers) met entry criteria and were considered to be eligible for this study.

Participant flow — Overall Study
MilestoneTreatment I: (DR-102)Treatment II
Started150143
Safety population145142
Intent-to-treat (itt) population140136
Per protocol (pp) population125121
Completed116114
Not completed3429
Withdrew: Adverse event109
Withdrew: Sponsor request97
Withdrew: Withdrawal by subject610
Withdrew: Lost to follow-up43
Withdrew: Protocol violation20
Withdrew: Noncompliance20
Withdrew: Pregnancy10

Outcome measures

PrimaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels

Normal range for this hemostatic parameter was 41 to 372 pmol/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · pmol/L
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels
pmol/LTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels45.0 ± 15.2456.8 ± 15.60
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.5892 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: -11.8 · 95% CI -54.75 to 31.17Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer

Normal range for this hemostatic parameter was 0 to 729 mcg/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · mcg/L
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer
mcg/LTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer16.4 ± 10.2913.4 ± 10.46
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.839 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 3.0 · 95% CI -25.96 to 31.94Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen

The normal range for this hemostatic parameter was 50% to 147%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · percentage of normal 50% to 147%
Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen
percentage of normal 50% to 147%Treatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen-11.4 ± 1.09-6.6 ± 1.10
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.0021 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: -4.8 · 95% CI -7.87 to -1.77Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity

The normal range for this hemostatic parameter was 70% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · percentage of normal
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity
percentage of normalTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity16.3 ± 1.9013.0 ± 1.93
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.2312 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 3.2 · 95% CI -2.08 to 8.58Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin

Normal range for this hemostatic parameter was 75% to 130%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · percentage of normal
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin
percentage of normalTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin-1.6 ± 1.17-3.2 ± 1.18
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.3440 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 1.6 · 95% CI -1.70 to 4.85Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity

Normal range for this hemostatic parameter was 70% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · percentage of normal
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity
percentage of normalTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity3.3 ± 0.213.0 ± 0.21
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.2522 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 0.3 · 95% CI -0.24 to 0.92Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII

Normal range for this hemostatic parameter was 60% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · percentage of normal
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII
percentage of normalTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII17.9 ± 0.8115.1 ± 0.82
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.0143 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 2.9 · 95% CI 0.58 to 5.13Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII

Normal range for this hemostatic parameter was 50% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · percentage of normal
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII
percentage of normalTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII11.1 ± 1.9210.6 ± 1.95
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.8507 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 0.5 · 95% CI -4.87 to 5.91Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance

This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 2.00 to 3.36. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · ratio
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance
ratioTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance-0.3 ± 0.02-0.4 ± 0.02
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.0459 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 0.1 · 95% CI 0.00 to 0.14Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance

This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 0.32 to 1.79. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · ratio
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance
ratioTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance0.8 ± 0.040.7 ± 0.04
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.0318 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 0.1 · 95% CI 0.01 to 0.26Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin

Normal range for this adrenal parameter was 1906.448 to 4520.504 mg/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · mg/L
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin
mg/LTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin4083.3 ± 159.453721.8 ± 162.95
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.1148 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 361.6 · 95% CI -88.45 to 811.61Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol

Normal range for this adrenal parameter was 85.6 to 618.2 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · nmol/L
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol
nmol/LTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol239.0 ± 15.67230.8 ± 16.03
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.7136 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 8.2 · 95% CI -35.92 to 52.39Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)

Normal range for this parameter was 0.35 to 5.5 mIU/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · mIU/L
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)
mIU/LTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)0.2 ± 0.070.3 ± 0.07
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.3903 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: -0.1 · 95% CI -0.29 to 0.11Least Squares mean difference: Treatment I - Treatment II
SecondaryLeast Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin

Normal range for this parameter was 28 to 146 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.

Time frame:
Baseline through Month 6
Reported as:
Least squares mean · nmol/L
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin
nmol/LTreatment I: (DR-102)Treatment II
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin163.4 ± 7.29149.1 ± 7.46
Statistical analysis
  • Treatment I: (DR-102) vs Treatment II · ANCOVA · p = 0.1731 (The p-value, least squares mean difference, and 95% CI for the treatment group comparison are based on a repeated measures ANCOVA with baseline, treatment, visit, and treatment-by-visit interaction as fixed factors, and subject as a random effect.) · Least squares mean difference: 14.3 · 95% CI -6.29 to 34.80Least Squares mean difference: Treatment I - Treatment II

Adverse events

Collected over Adverse events/serious adverse events were collected from the time of signed informed consent until the the Final Telephone Contact (14 days after completing investigational product) or the Early Termination Visit. Treatment period was 6 28-day cycles.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment I: (DR-102)—0/145 (0%)84/145 (57.9%)
Treatment II—1/142 (0.7%)66/142 (46.5%)
Most frequent serious events
Most frequent serious events
EventTreatment I: (DR-102)Treatment II
AppendicitisInfections and infestations0/1451/142
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTreatment I: (DR-102)Treatment II
MetrorrhagiaReproductive system and breast disorders50/14528/142
HeadacheNervous system disorders9/14516/142
Alpha globulin increasedInvestigations11/1458/142
Prothrombin level increasedInvestigations8/1457/142
DysmenorrhoeaReproductive system and breast disorders4/1457/142
Breast painReproductive system and breast disorders5/1452/142
GastroenteritisInfections and infestations1/1454/142
InfluenzaInfections and infestations1/1454/142
NauseaGastrointestinal disorders4/1452/142
DizzinessNervous system disorders4/1450/142

Baseline characteristics

Safety Population (all randomized participants who took 1 or more doses of study drug)

Age, Continuous
Age, Continuous(years)Treatment I: (DR-102)Treatment IITotal
Mean26.4 ± 4.9827.0 ± 5.2626.7 ± 5.12
Sex: Female, Male
Sex: Female, Male(Participants)Treatment I: (DR-102)Treatment IITotal
Female145142287
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Treatment I: (DR-102)Treatment IITotal
White140136276
Black112
Asian011
American Indian or Alaskan Native011
Other437
Weight
Weight(kg)Treatment I: (DR-102)Treatment IITotal
Mean61.6 ± 10.3560.1 ± 9.3660.9 ± 9.89
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Treatment I: (DR-102)Treatment IITotal
Mean22.9 ± 3.6222.4 ± 3.0622.6 ± 3.36
08

Study locations

27 sites
  • Teva Investigational Site 32064
    Essen, 45127, Germany
  • Teva Investigational Site 32066
    Frankfurt am Main, 60439, Germany
  • Teva Investigational Site 32065
    Frankfurt, 60311, Germany
  • Teva Investigational Site 32062
    Hamburg, 22159, Germany
  • Teva Investigational Site 32063
    Hamburg, 22359, Germany
  • Teva Investigational Site 32061
    Magdeburg, 39112, Germany
  • Teva Investigational Site 80013
    Givataim, 53425, Israel
  • Teva Investigational Site 80015
    Haifa, 34466, Israel
  • Teva Investigational Site 80017
    Modi'in, 71705, Israel
  • Teva Investigational Site 80014
    RishonLe'zio, Israel
  • Teva Investigational Site 80018
    Tel-Aviv, 62304, Israel
  • Teva Investigational Site 80016
    Tel-Aviv, 69379, Israel
  • Teva Investigational Site 30014
    Brescia, 25123, Italy
  • Teva Investigational Site 30009
    Cagliari, 09124, Italy
  • Teva Investigational Site 30012
    Catania, 95123, Italy
  • Teva Investigational Site 30013
    Napoli, 80131, Italy
  • Teva Investigational Site 30010
    Pavia, 27100, Italy
  • Teva Investigational Site 30007
    Pisa, 56126, Italy
  • Teva Investigational Site 30016
    Siena, 53100, Italy
  • Teva Investigational Site 31017
    Barcelona, 08025, Spain
  • Teva Investigational Site 31015
    Barcelona, 08028, Spain
  • Teva Investigational Site 31014
    Barcelona, 08035, Spain
  • Teva Investigational Site 31016
    Gava, Barcelona, 08850, Spain
  • Teva Investigational Site 31012
    Lugo, 27002, Spain
  • Teva Investigational Site 31010
    Madrid, 28001, Spain
  • Teva Investigational Site 31011
    Madrid, 28009, Spain
  • Teva Investigational Site 31009
    Vitoria-Gasteiz, 01004, Spain
09

References and documents

Publications

  • Peters K, Gordon N, Ricciotti N, Hsieh J, Howard B, Weiss H. Hemostatic effects of two desogestrel-containing combined oral contraceptive regimens: a multinational, multicenter, randomized, open-label study. Clin Exp Obstet Gynecol. 2016;43(3):334-40. PubMed 27328486 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Sep 2012, 10 months.

Results were first posted in Nov 2013, 1 year 1 month after primary completion.

Of 22 phase 2 interventional studies under Thrombosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2011
First posted
Jul 6, 2011
StartActual
Oct 31, 2011
Primary completionActual
Sep 30, 2012
CompletionActual
Sep 30, 2012
Results first posted
Nov 27, 2013
Last update
Dec 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01388491
Responsible party
Sponsor
First posted
Jul 6, 2011
Start date
Oct 31, 2011
Primary completion
Sep 30, 2012
Completion
Sep 30, 2012
Results posted
Nov 27, 2013
Last update
Dec 6, 2021

Study contacts

Teva Women's Health Research Protocol Chair
study chair · Teva Women's Health Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desogestrel · Ethinyl Estradiol

Start the discussion